Lisocabtagene maraleucel may induce remission in relapsed chronic lymphocytic leukemia (CLL)
1. Complete response or remission was reported in 18% of patients who received a single liso-cel infusion. 2. Nearly 10% ...
Tag: hematologic malignancy
Quizartinib improves overall median survival in patients with acute myeloid leukemia
1. Overall survival in the quizartinib group was 31.9 months compared to 15.1 months in the placebo group. 2. Proportion ...
#VisualAbstract: Carfilzomib, dexamethasone, and lenalidomide superior to lenalidomide monotherapy for multiple myeloma
Click to read this study in The Lancet Oncology.
Momelotinib reduces symptom burden compared to danazol in patients with myelofibrosis
1. After a 24-week treatment period, a significantly greater proportion of patients randomized to momelotinib had symptom scores reduced by ...
#VisualAbstract: Rituximab plus lenalidomide shows comparable survival compared to chemotherapy for CD20⁺ follicular lymphoma
Click to read this study in the Journal of Clinical Oncology.
#VisualAbstract: Immunocompromised individuals may be at an increased risk of metastses with cutaneous squamous cell carcinomas
Click to read this study in the Journal of the American Academy of Dermatology.
Biologic teclistamab shows promise in treatment of refractory multiple myeloma in phase 1 drug study
1. Patients on the recommended phase 2 dosage of teclistamab had no dose-limiting adverse events. 2. There was a 65% ...
KTE-X19 may induce remission in patients with relapsed or refractory B-cell lymphoblastic leukemia
1. 71% patients achieved complete remission or complete remission with incomplete recovery following KTE-X19 infusion. 2. The majority of adverse ...
COVID-19 susceptibility may be increased in patients with hematological malignancies compared to solid organ tumours
1. Patients with hematological malignancies were found to be at an increased risk of COVID-19 and were more likely to ...